Anthem (NYSE:ANTM) Releases FY 2019 Earnings Guidance

Share on StockTwits

Anthem (NYSE:ANTM) issued an update on its FY 2019 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $19.30 for the period.

NYSE ANTM opened at $251.79 on Thursday. Anthem has a fifty-two week low of $227.16 and a fifty-two week high of $317.99. The stock’s 50-day moving average is $269.17 and its two-hundred day moving average is $279.12. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.64 and a quick ratio of 1.64. The firm has a market cap of $66.15 billion, a P/E ratio of 15.85, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Anthem (NYSE:ANTM) last posted its earnings results on Wednesday, July 24th. The company reported $4.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.61 by $0.03. Anthem had a return on equity of 15.02% and a net margin of 4.21%. The company had revenue of $25.20 billion for the quarter, compared to analyst estimates of $24.88 billion. During the same period last year, the company earned $4.25 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year. On average, equities analysts expect that Anthem will post 19.36 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.20 annualized dividend and a yield of 1.27%. Anthem’s dividend payout ratio (DPR) is currently 20.14%.

Several equities research analysts have recently issued reports on the company. Deutsche Bank assumed coverage on Anthem in a research report on Thursday, September 12th. They issued a buy rating on the stock. Wells Fargo & Co reaffirmed a buy rating on shares of Anthem in a research report on Friday, July 26th. Morgan Stanley raised their price target on Anthem from $359.00 to $371.00 and gave the company an overweight rating in a research report on Friday, July 12th. Zacks Investment Research downgraded Anthem from a buy rating to a hold rating and set a $289.00 price target on the stock. in a research report on Monday, August 19th. Finally, ValuEngine downgraded Anthem from a hold rating to a sell rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $325.93.

In other news, Director Robert L. Dixon, Jr. sold 520 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $294.11, for a total value of $152,937.20. Following the sale, the director now directly owns 9,971 shares of the company’s stock, valued at $2,932,570.81. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.17% of the company’s stock.

About Anthem

Anthem, Inc, through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets.

Recommended Story: Equal Weight Rating

Earnings History and Estimates for Anthem (NYSE:ANTM)

Receive News & Ratings for Anthem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthem and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Investment Analysts’ Price Target Changes for October, 14th
Investment Analysts’ Price Target Changes for October, 14th
Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.